SVB Leerink Weighs in on Affimed’s Q3 2021 Earnings (NASDAQ:AFMD)

Affimed (NASDAQ:AFMD) – Research analysts at SVB Leerink issued their Q3 2021 earnings estimates for Affimed in a report issued on Tuesday, October 12th. SVB Leerink analyst D. Graybosch expects that the biopharmaceutical company will post earnings per share of ($0.02) for the quarter. SVB Leerink has a “Outperform” rating and a $12.00 price objective on the stock. SVB Leerink also issued estimates for Affimed’s Q4 2021 earnings at ($0.05) EPS, FY2021 earnings at ($0.25) EPS, FY2022 earnings at ($0.28) EPS, FY2023 earnings at $0.09 EPS, FY2024 earnings at $0.24 EPS and FY2025 earnings at $0.22 EPS.

Affimed (NASDAQ:AFMD) last announced its earnings results on Tuesday, September 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.10). The business had revenue of $11.70 million for the quarter, compared to analyst estimates of $13.57 million. Affimed had a negative return on equity of 34.91% and a negative net margin of 91.76%. During the same period in the previous year, the company earned ($0.18) earnings per share.

Several other analysts have also recently commented on AFMD. Stifel Nicolaus began coverage on Affimed in a research report on Wednesday, September 29th. They set a “buy” rating and a $12.00 price target for the company. Zacks Investment Research cut Affimed from a “hold” rating to a “strong sell” rating in a research report on Monday, September 13th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $12.83.

Shares of AFMD opened at $5.85 on Thursday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.37 and a current ratio of 3.38. Affimed has a one year low of $3.09 and a one year high of $11.74. The stock has a market capitalization of $574.98 million, a price-to-earnings ratio of -12.72 and a beta of 2.67. The stock has a 50 day moving average price of $6.32 and a 200 day moving average price of $7.70.

A number of large investors have recently modified their holdings of AFMD. Point72 Asset Management L.P. grew its holdings in Affimed by 71.9% in the 1st quarter. Point72 Asset Management L.P. now owns 5,285,708 shares of the biopharmaceutical company’s stock valued at $41,810,000 after buying an additional 2,210,708 shares in the last quarter. BlackRock Inc. grew its holdings in Affimed by 31.6% in the 1st quarter. BlackRock Inc. now owns 7,028,783 shares of the biopharmaceutical company’s stock valued at $55,598,000 after buying an additional 1,687,215 shares in the last quarter. Sphera Funds Management LTD. purchased a new stake in Affimed in the 1st quarter valued at $8,060,000. 683 Capital Management LLC lifted its stake in shares of Affimed by 19.2% in the 1st quarter. 683 Capital Management LLC now owns 5,114,712 shares of the biopharmaceutical company’s stock valued at $40,458,000 after purchasing an additional 825,000 shares during the last quarter. Finally, Canada Pension Plan Investment Board lifted its stake in shares of Affimed by 338.6% in the 1st quarter. Canada Pension Plan Investment Board now owns 1,057,000 shares of the biopharmaceutical company’s stock valued at $8,361,000 after purchasing an additional 816,000 shares during the last quarter. Institutional investors own 72.98% of the company’s stock.

About Affimed

Affimed NV engages in the discovery and development of cancer immunotherapies. It offers ROCK novel proprietary antibody platform, which delivers types of next-generation tetravalent antibody formats, including bispecific and trispecific innate cell engagers. It operates through the following geographical segments: Germany, Europe, and USA.

Featured Article: The risks of owning bonds

Earnings History and Estimates for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.